Compare VanEck Gold Miners ETF (GDX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Natera Inc. Common Stock — how do they compare? VanEck Gold Miners ETF trades at $85.12 (market cap $26.33B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.2× VanEck Gold Miners ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and Natera Inc. Common Stock for 0 Days on average.
| GDX | NTRA | |
|---|---|---|
Market Cap | $26.33B | $57.03B |
Volume | 15,141,546 | 1,131,157 |
52-Week High | $115.84 | $425.64 |
52-Week Low | $68.28 | $179.42 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% on the day, with technical indicators showing a neutral to bearish bias amid mixed signals from moving averages and oscillators. The ETF's fundamental metrics are not provided in the snapshot, but recent news highlights ongoing institutional repositioning and comparisons between gold miners and physical gold. Support and resistance levels are tightly clustered around the current price, suggesting near-term consolidation.
The outlook for GDX hinges on gold price trends and interest rate movements, with potential upside from inflation hedging demand but risks from institutional selling and metal volatility. Investors face a balanced risk-reward scenario given neutral sentiment and lack of clear directional catalysts.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
